ArticleCureus2024
Isolated Ophthalmoplegia: An Uncommon Presentation of Anti-glutamic Acid Decarboxylase 65 (Anti-GAD65) Neurological Syndrome.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oculomotor Abnormalities in Anti-Glutamic Acid Decarboxylase-Positive Stiff Person Syndrome.Neurology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolated ophthalmoplegia as an anti-glutamic acid decarboxylase 65 (anti-GAD65) antibody-associated neurological syndrome is rare. We present a case of a 22-year-old pregnant Hispanic female patient who presented initially with a left oculomotor nerve palsy following an emergency department (ED) visit for migraine headache. Brain imaging was done with no important findings. The patient was managed with pyridostigmine as a myasthenia gravis diagnosis was suspected but no response was seen. Left oculomotor palsy went on to improve gradually with a course of oral steroids; however, on her third-month follow-up, the patient developed a worsening diplopia episode revealing a new left abducens nerve palsy followed by right oculomotor and trochlear nerve palsies in a period of less than one month. An autoimmune encephalitis panel was made which came back positive for anti-GAD65. A recommendation was made to start intravenous immunoglobulin (IVIG); however, the insurance company only approved mycophenolate mofetil which went on to mitigate the aforementioned palsies. Our case supports the efficacy of steroids and mycophenolate mofetil as reasonable immunomodulators for GAD65-associated neurological syndromes. However, further research is needed to determine the best appropriate treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.